- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Melissa Andel Previews Her Upcoming Session on Drug Pricing Reform at AMCP 2022
Melissa Andel, principal at CommonHealth Solutions, previewed her session on policy making and pricing reform at the upcoming Academy of Managed Care Pharmacy's annual meeting.
Melissa Andel, principal at CommonHealth Solutions, previewed her session on policy making and pricing reform at the upcoming Academy of Managed Care Pharmacy's annual meeting.
Transcript
What will you be talking about during your session at AMCP 2022?
So, my session is just going to be an update on what's going on here in [Washington,] DC, mainly with regard to Congress, as well as what the Biden administration has been working on with respect to drug price reform. So, not just reconciliation, but also some of the administrative rules that HHS has, which also includes CMS and HRSA [Health Resources and Services Administration], and some of the actions that the Biden administration has been working on and what that means for patients and payers and manufacturers.
What other presentations are you looking forward to checking out at AMCP 2022?
Oh, yeah, so I've got a couple. I was filling out my agenda the other day. But yeah, there's a couple on digital therapeutics that I'm looking forward to and also a few on value-based purchasing contracts and 340B and the Medicaid pharmacy benefit that I'm looking forward to attending. So, the sessions that are on some of the newer trends that are facing payers and the industry are always interesting to me.
The Challenge of Addressing Drug Spend to Drive Down Total Cost of Care in EOM
October 27th 2024Stuart Staggs, vice president of transformation and shared services at McKesson, explained that oncology practices in the Enhancing Oncology Model (EOM) have a tough job driving down costs when drug costs make up a larger portion of the total cost of care.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Targeting Progression: Amivantamab’s Role in NSCLC After Osimertinib
October 24th 2024Amivantamab's role in non–small cell lung cancer (NSCLC) has been a highlight of the lung cancer space this year, with the 2 most recent approvals based on data from the MARIPOSA and MARIPOSA-2 trials.
Read More
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More
